News

Rasuvo, which is currently under FDA review, is being developed for multiple indications, including rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis. The drug is designed to improve

AKB-6548, a once-daily, oral investigational therapy, is designed to achieve a coordinated and natural increase in red blood cell production and iron utilization that is similar to the

RLB Holdings managing partner and co-founder Lydia Bartoszek said: "The vision of Kineta-RLB is to progress the clinical development in high need areas with the hope of improving

Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestisstarting in April 2014. Probi has already delivered

New participant Novo Ventures and existing investor Third Rock Ventures co-led this round of financing, which also included founding investor SV Life Sciences. Novo Ventures senior partner Dr

Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending Abbreviated New Drug Application (ANDA)

The once-weekly treatment of albiglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), is administered using an injector pen supplied with a 5mm 29-gauge thin-walled needle. GLP-1 is an important

Launch of Viorra in Mexico is expected later in 2014, subject to the regulatory approvals and finalizing the sourcing out of a suitable manufacturing partner. The company said

FDA action extends Kuvan’s market exclusivity to June 2015 and is based on trials submitted in response to a written request by the FDA to investigate the use